Key facts
- This page summarizes Karin Eastham's Form 4 filing for NEKTAR THERAPEUTICS (NKTR).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 20 Sep 2022, 20:47.
Karin Eastham - 16 Sep 2022 Form 4 Insider Report for NEKTAR THERAPEUTICS (NKTR)
- Reporting relationship
- Director
- Issuer ticker
- NKTR
- Reported as of
- 16 Sep 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 20 Sep 2022, 20:47:33 UTC
- Prior SEC filing
- 14 Sep 2022
- Next SEC filing
- 17 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- Mark A. Wilson, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Karin Eastham filed Form 4 for NEKTAR THERAPEUTICS (NKTR) on 20 Sep 2022.
Change
- Previous filing in this sequence was filed on 14 Sep 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NKTR
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +10,200
- Change %
- +78%
- Price
- $0.000000
- Shares after
- 23,233
- Date
- 16 Sep 2022
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NKTR
transaction
Derivative
Stock Option
Award
- Transaction value
- $0
- Shares
- +20,400
- Change %
- Price
- $0.000000
- Shares after
- 20,400
- Date
- 16 Sep 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,400
- Exercise price
- $3.47
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.
Footnote F2
This RSU award vests in full, one year following September 16, 2022.
Footnote F3
This stock option vests in equal monthly installments over the one-year period beginning on September 16, 2022.